# Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

> **NCT02133924** · PHASE2 · COMPLETED · sponsor: **John Levine** · enrollment: 76 (actual)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** natalizumab
- **DRUG:** steroids

## Key facts

- **NCT ID:** NCT02133924
- **Lead sponsor:** John Levine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2020-12-10
- **Final completion:** 2021-11-21
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133924, "Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02133924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*